 Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold |
| It is an object of the invention to provide a method of affecting nociception. It is an object of ... |
|
| Liposomal transfection method |
| The object of the present invention is thus a method for transfecting a cell with a nucleic acid ... |
|
| Antihelminthic anthraquinones and method of use thereof |
| OF THE INVENTION All patents, patent applications, government publications, government regulations,... |
|
| Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| The invention is directed to a new method of inducing viral mutagenesis which is useful in cell ... |
|
| 2'-Fluoronucleosides |
| OF THE INVENTION The invention as disclosed herein is a compound, method and composition for the ... |
|
| Nucleoside compounds |
| Where the following terms are used in this specification, they are used as defined below. The ... |
|
| Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| OF THE INVENTION In one embodiment, the viral infection is chosen from Flaviviridea viral ... |
|
| Monocyclic L-nucleosides, analogs and uses thereof |
| Where the following terms are used in this specification, they are used as defined below. The term ... |
|
| Storage medium storing catalog information and corresponding audio data |
| It is an object of the present invention to provide a storage medium for storing catalog ... |
|
| Nucleoside compounds and uses thereof |
| The present invention is directed to nucleoside analogs and related compounds, including their ... |
|
|
Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
| Details |
Inventors: Sorgente, Nino; Nakamura, Robert M.;
Assignee: Immudyne, Inc. (Houston, TX)
Primary Examiner: Reamer; James H.
Assistant Examiner:
Attorney, Agent or Firm: Fitting; Thomas
The invention describes compositions and methods for treatment of rheumatoid arthritis and osteoarthritis. The compositions comprise insoluble, native collagen Type II in a particular form in combinations with other active agents, including glucosamine, chondroitin, ascorbate, boron and magnesium. Also described are methods for producing particulated insoluble native collagen Type II. |
|
DETAILED DESCRIPTION OF THE INVENTION The invention describes methods and compositions for the treatment of rheumatoid arthritis and osteoarthritis and other conditions that manifest cartilage degradation and inflammation particularly of the joints, but including other cartilages.
Rheumatoid arthritis usually refers to an autoimmune systemic disorder that is accompanied by severe inflammation of the joints.
Osteoarthritis is not an immunological disorder and is not a systemic disease, it affects only cartilage.
However, the end result of both diseases on cartilage is the same, namely degradation and destruction of cartilage associated with pain, swelling, inflammation, joint enlargement and deformity.
In the intestine, the presentation of an antigen to the immune system is mediated by the cells of the Peyer's patch.
Like all antigen presenting cells, Peyer's patch cells respond more easily to large, particulate antigens than to small soluble antigens.
It is therefor preferred that the collagen Type II antigen used in the present case be in an insoluble particulate form to elicit a greater response.
A.
Methods for Purification of Insoluble Native Collagen Type II The present invention describes a process for the purification of an insoluble collagen Type II from cartilage in a form that is highly effective in eliciting immunological tolerance when administered as an oral composition.
The invention also describes methods for the purification of chondroitin sulfate from the same cartilage processed by the present methods for isolating insoluble collagen.
To that end, cartilage is first collected by isolating sections of tissue containing cartilage, such as sternum, scapula, nasal septum, and the like tissues.
Cartilage is then cleaned of all adhering soft tissues and of the perichondrium, diced into small pieces of about 0.
2 to 5 cm.
sup.
2, preferably about 0.
5 to 2 cm.
sup.
2, and extracted with 0.
5 to 5.
0 molar (M), preferably about 1.
0 M, guanidinium hydrochloride; after 24-48 hours the remaining insoluble cartilage pieces (collagen) are separated from the liquid by filtration
|
|
Gene Therapy 
